Granted Patent B2

US 12,677,812 · App. 18/137,110 · Granted Jul 14, 2026

Inventors: Lynn Macdonald (Harrison, NY); Sean Stevens (Del Mar, CA); Andrew J. Murphy (Croton-on-Hudson, NY); Margaret Karow (Santa Rosa Valley, CA); John McWhirter (Greenville, NC)

Assignee: Regeneron Pharmaceuticals, Inc.

A01K67/0278A01K67/0276C07K16/461A01K2207/15A01K2217/072A01K2217/075A01K2217/15A01K2227/105

Abstract

Claims (23)

1 . A method of producing a human immunoglobulin heavy chain variable domain sequence, the method comprising:

(a) immunizing a genetically modified mouse with an antigen of interest, wherein the mouse comprises in its germline genome:

(i) an unrearranged human genomic sequence comprising a single human V H gene segment, one or more D H gene segments, and one or more J H gene segments, wherein the single human V H gene segment, the one or more D H gene segments, and the one or more J H gene segments are operably linked to a mouse immunoglobulin heavy chain constant region gene at the endogenous immunoglobulin heavy chain locus, wherein insertion of the unrearranged human genomic sequence disrupts the function of an endogenous ADAM6 protein, and wherein the disruption of the endogenous ADAM6 function is associated with a reduction in fertility in male mice; and

(ii) a nucleic acid sequence that encodes a mouse ADAM6 protein that is functional in a male mouse, wherein the mouse ADAM6 protein is expressed if the mouse is a male mouse such that the male mouse is fertile; and

wherein B cells of the genetically modified mouse express antibodies in response to exposure to an antigen, wherein each antibody includes two immunoglobulin light chains paired with two immunoglobulin heavy chains, wherein each heavy chain comprises a human heavy chain variable domain expressed from a human heavy chain variable region sequence including a V H gene segment that is identical to, or a somatically hypermutated version of, the single human V H gene segment;

(b) allowing the genetically modified mouse to mount an immune response with respect to the antigen of interest;

(c) obtaining a B cell from the genetically modified mouse that expresses an antibody that specifically binds the antigen of interest; and

(d) determining an amino acid sequence of a human heavy chain variable domain of the antibody expressed by the B cell, wherein the antibody specifically binds the antigen of interest; and

(e) producing the human heavy chain variable domain.

2 . The method of claim 1 , wherein the single human V H gene segment in the germline genome of the mouse is a V H 1-3, V H 1-8, V H 1-18, V H 1-24, V H 1-45, V H 1-46, V H 1-58, V H 2-5, V H 2-26, V H 2-70, V H 3-7, V H 3-9, V H 3-11, V H 3-13, V H 3-15, V H 3-16, V H 3-20, V H 3-21, V H 3-23, V H 3-30, V H 3-30-3, V H 3-30-5, V H 3-33, V H 3-35, V H 3-38, V H 3-43, V H 3-48, V H 3-49, V H 3-53, V H 3-64, V H 3-66, V H 3-72, V H 3-73, V H 3-74, V H 4-4, V H 4- 28, V H 4-30-1, V H 4-30-2, V H 4-30-4, V H 4-31, V H 4-34, V H 4-39, V H 4-59, V H 4-61, V H 5-51, V H 6-1, V H 7-4-1, V H 7-81 or a polymorphic variant thereof.

3 . The method of claim 1 , wherein the mouse comprises endogenous V H gene segments that are incapable of rearranging.

4 . The method of claim 1 , wherein the unrearranged human genomic sequence in the germline genome of the mouse comprises the single human V H gene segment, 27 human D H gene segments, and six human J H gene segments.

5 . The method of claim 1 , wherein the germline genome of the mouse further comprises one or more human VK gene segments and one or more human JK gene segments.

6 . The method of claim 1 , wherein the one or more human Vκ gene segments and one or more human Jκ gene segments are present at an endogenous immunoglobulin light chain locus.

7 . The method of claim 1 , wherein the germline genome of the mouse further comprises one or more human Vλ gene segments and one or more human JA gene segments.

8 . The method of claim 7 , wherein the one or more human VA gene segments and one or more human Jλ gene segments are present at an endogenous immunoglobulin light chain locus.

9 . The method of claim 1 , wherein immunizing with the antigen of interest of step (a) is carried out with protein, DNA, a combination of DNA and protein, or cells expressing the antigen of interest.

10 . The method of claim 1 , wherein the mouse is a male mouse.

11 . The method of claim 1 , wherein the nucleic acid encoding the mouse ADAM6 protein is inserted so that it is contiguous with the unrearranged human genomic nucleic acid.

12 . The method of claim 1 , wherein the nucleic acid encoding the mouse ADAM6 protein is present at an endogenous immunoglobulin heavy chain locus.

13 . The method of claim 1 , wherein the nucleic acid encoding the mouse ADAM6 protein is inserted at a position in the mouse germline genome other than the endogenous immunoglobulin heavy chain locus.

14 . The method of claim 1 , wherein the endogenous heavy chain variable locus is inactivated by replacing the endogenous V H gene segments with the unrearranged human genomic nucleic acid.

15 . The method of claim 1 , wherein the ADAM6 protein comprises ADAM6a and/or ADAM6b.

Assignments (2)

Continuity (7)

References Cited (400)